Fox Chase Cancer CenterPhiladelphia, Pennsylvania, United States
Disclosure information not submitted.
Paper 10 - THE NOVEL KIT INHIBITOR IDRX-42 SHOWS PROMISING ACTIVITY IN 2ND AND LATER-LINE GASTROINTESTINAL STROMAL TUMORS: RESULTS FROM A PHASE 1 STUDY (STRATEGIST 1)
Thursday, November 14, 202410:30 AM – 11:30 AM PST
Debate #1: SHOULD WE TRY TO PREVENT DRUG RESISTANCE THROUGH EARLIER COMBINATION TREATMENT OR STEER AND TARGET DRUG RESISTANCE WHEN IT DEVELOPS?
Thursday, November 14, 202411:30 AM – 12:15 PM PST
Paper 66 - CHARACTERIZING THE GENOMIC LANDSCAPE OF MALIGNANT PERIVASCULAR EPITHELIOID CELL FAMILY OF TUMORS IN A REAL-WORLD PATIENT POPULATION USING THE FOUNDATION MEDICINE GENOMIC DATABASE
Friday, November 15, 20244:00 PM – 5:00 PM PST
